Real life clinical outcomes of relapsed/refractory diffuse large B cell lymphoma in the rituximab era: The STRIDER study.

ABSTRACT:

Background

Relapse and refractory (R/R) rates after first-line R-CHOP in diffuse large B cell lymphomas (DLBCL) are ~40% and ~15% respectively.

Aims

We conducted a retrospective real-world analysis aimed at evaluating clinical outcomes of R/R DLBCL patients.

Material and methods

Overall, 403 consecutive DLBCL patients treated in two large hematological centers in Torino, Italy were reviewed.

Results

At a median follow up of 50 months, 5-year overall survival from diagnosis (OS-1) was 66.5%, and 2-year progression free survival (PFS-1) was 68%. 134 (34.4%) patients relapsed (n = 46, 11.8%) or were refractory (n = 88, 22.6%) to R-CHOP. Most employed salvage treatments included platinum salt-based regimens in 38/134 (28.4%), lenalidomide in 14 (10.4%). Median OS a

SUBMITTER: Dogliotti I 

PROVIDER: S-EPMC11258436 | biostudies-literature | 2024 Jul

REPOSITORIES: biostudies-literature